SEC Tracker
Get the app

Drugs Made In America Acquisition DMAA

Drugs Made In America Acquisition Q1 FY26: net income $2.0M, up 57%

Form
10-Q
Filed
Period
Importance
Notable

Key figures from this report

These are the numbers Drugs Made In America Acquisition reported for Q1 FY26, the quarter ended Mar 31, 2026, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.

  1. Net income$2.0M+57% from $1.3M in Q1 FY2510-Q income statement, on EDGAR
  2. Cash and cash equivalents$15K+1513% from $923 in Q1 FY2510-Q balance sheet, on EDGAR
  3. Cash from operations−$91KAgainst −$251K in Q1 FY2510-Q cash flow statement, on EDGAR

Every quarter in the financial tables

View on EDGAR

Open in the app

Get an email when Drugs Made In America Acquisition files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 6770 and related industry codes: the same peer list as the financial tables.

  1. Archimedes Tech SPAC Partners II ATII public float $235M, Jun 30, 2025
  2. Fifth Era Acquisition Corp I FERA public float $236M, Jun 30, 2025
  3. Sizzle Acquisition Corp. II SZZL public float $233M, Jun 30, 2025
  4. GSR IV Acquisition GSRF public float $236M, Jun 30, 2025
  5. Jena Acquisition Corp II JENA public float $236M, Jun 30, 2025